<DOC>
	<DOCNO>NCT00547365</DOCNO>
	<brief_summary>RATIONALE : Antibodies , human immune globulin , block growth abnormal cell different way . Some block ability abnormal cell grow spread . Others find abnormal cell help kill carry cell-killing substance . Giving human immune globulin may effective treat patient primary amyloidosis cause heart dysfunction . PURPOSE : This phase I/II trial study side effect best dose human immune globulin see well work treat patient primary amyloidosis cause heart dysfunction .</brief_summary>
	<brief_title>Human Immune Globulin Treating Patients With Primary Amyloidosis That Causing Heart Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : - Establish maximum tolerate dose human immune globulin intravenous ( IGIV ) give weekly first 3 month bi-weekly 9 additional month patient cardiac-associated primary light chain-associated ( AL ) amyloidosis . - Determine safety , pharmokinetics , therapeutic efficacy evidence titer serum fibril-reactive immunoglobulin G ( IgG ) antibodies pre- post-IGIV infusion . - Demonstrate stable improve organ function . OUTLINE : Patients receive human immune globulin IV ( IGIV ) weekly 3 month biweekly 9 month , total 12 month absence disease progression unacceptable toxicity . Patients undergo blood sample collection measure serum anti-fibril antibody titer pre- post- IGIV infusion assess safety response treatment .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<criteria>Inclusion criterion : Confirmed diagnosis cardiacassociated primary ( AL ) amyloidosis base accepted clinical laboratory criterion Patients must heart involvement evidence elevated serum brain natriuretic peptide ( BNP ) , troponin level , and/or 2D echocardiography evidence thicken intraventricular septum ( IVS ) . Life expectancy &gt; 3 month Prior concurrent chemotherapy drugbased antiAL regime allow Exclusion criterion : NonAL amyloidosis New York Heart Association ( NYH ) class IV heart disease Significant comorbidity ( e.g. , uncontrolled infection , diabetes , serious illness )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>